- The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's LTRN LP-184 for glioblastoma multiforme (GBM) and other malignant gliomas.
- The news follows the recent announcement of the FDA granting LP-184 Orphan Drug tag for pancreatic cancer.
- LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.
- Related Content: LP-184 Inhibits Tumor Growth, Improves Survival In Animals Models Of Glioblastoma
- Related content: Benzinga's Full FDA Calendar
- Price action: LTRN shares are down 1.14% at $13.90 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
